Drug intelligence / Profile preview

NBG025

Development stage: Preclinical
Lead developer: NB Health Laboratory
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NBG025 is a monoclonal antibody drug candidate developed by NB Health Laboratory. It acts as a modulator of the lysophosphatidic acid receptor 1 (LPAR1), also known as Edg-2. The primary therapeutic area under investigation for this agent is fibrosis. As of March 2025, its highest global development status is preclinical. The mechanism involves modulation of LPAR1 signaling, which has been implicated in fibrotic processes across various tissues.

Targets

LPAR1 (Lysophosphatidic acid receptor 1)

Beyond the preview

Go deeper on NBG025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBG025.

Explore the full profile